Microbot Medical Inc. (MBOT)

Microbot Medical Inc. (MBOT) Healthcare & Pipeline Overview

Microbot Medical Inc. is a pre-clinical stage medical device company specializing in robotic endoluminal surgery devices, including ViRob and TipCAT, targeting minimally invasive procedures. The company focuses on developing innovative solutions for hydrocephalus and endovascular interventions, supported by a strategic collaboration with Stryker Corporation and a growing patent portfolio.

What Is the Investment Thesis for MBOT?

Microbot Medical Inc. presents a notable research candidate in the robotic surgery space, driven by its innovative technologies and strategic partnerships. The company's focus on minimally invasive endoluminal surgery addresses a growing market need for less invasive and more precise surgical procedures. Key value drivers include the potential commercialization of its ViRob and TipCAT technologies, particularly the Self Cleaning Shunt for hydrocephalus, which could significantly improve patient outcomes. The strategic collaboration with Stryker Corporation provides validation and potential for future growth. However, as a pre-clinical stage company, Microbot Medical faces significant regulatory and commercialization risks. Successful navigation of regulatory pathways and securing market adoption are crucial for realizing the company's potential. Investors should closely monitor clinical trial progress, regulatory approvals, and partnership developments.

Based on FMP financials and quantitative analysis

MBOT Key Highlights

• Strategic collaboration with Stryker Corporation for technology co-development, enhancing market access and validation.
• Portfolio of 42 issued/allowed patents and 23 patent applications pending worldwide, protecting its innovative technologies.
• Focus on minimally invasive surgery with technologies like ViRob and TipCAT, addressing a growing market demand.
• Development of Self Cleaning Shunt for hydrocephalus, targeting a significant unmet clinical need.
• Pre-clinical stage company with potential for significant growth upon successful commercialization of its technologies.

Who Are MBOT's Competitors?

MBOT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MBOT's Key Strengths?

• Innovative robotic technologies for minimally invasive surgery.
• Strong intellectual property portfolio.
• Strategic collaboration with Stryker Corporation.
• Focus on unmet clinical needs (e.g., hydrocephalus).

What Are MBOT's Weaknesses?

• Pre-clinical stage company with no current revenue.
• Dependence on regulatory approvals and clinical trial success.
• Limited financial resources.
• Small number of employees (20).

What Could Drive MBOT Stock Higher?

• Completion of pre-clinical studies for ViRob and TipCAT technologies.
• Submission of regulatory filings for the Self Cleaning Shunt.
• Continued collaboration with Stryker Corporation on technology co-development.
• Expansion of the intellectual property portfolio through new patent applications.

What Are the Key Risks for MBOT?

• Negative return on equity (-21.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approvals for its medical devices.
• Delays in clinical trials and commercialization timelines.
• Competition from established medical device companies with greater resources.
• Dependence on external funding to support research and development activities.

What Are the Growth Opportunities for MBOT?

• Self Cleaning Shunt for Hydrocephalus: Microbot Medical's Self Cleaning Shunt addresses a critical need in the treatment of hydrocephalus and normal pressure hydrocephalus. The global market for hydrocephalus shunts is estimated at several hundred million dollars annually. Successful development and commercialization of this product could provide a significant revenue stream for Microbot Medical, offering a potentially superior solution compared to existing shunt technologies. The timeline for market entry depends on clinical trial results and regulatory approvals.
• ViRob for Endovascular Interventions: The ViRob technology, a disposable robot for endovascular interventional procedures, represents a significant growth opportunity. The market for endovascular devices is substantial and growing, driven by the increasing prevalence of cardiovascular diseases. ViRob's unique capabilities could enable more precise and less invasive interventions, potentially capturing a share of this large market. Clinical trials and regulatory approvals are key milestones for realizing this opportunity.
• TipCAT Modular Robotic System: The TipCAT system offers a versatile platform for various minimally invasive procedures. Its modular design allows for customization and adaptation to different surgical needs. This flexibility could attract a wide range of clinical applications and partnerships. The market for modular robotic systems is expanding, driven by the demand for adaptable surgical solutions. Successful development and marketing of TipCAT could establish Microbot Medical as a key player in this segment.
• Strategic Partnerships and Collaborations: Microbot Medical's collaboration with Stryker Corporation is a significant growth catalyst. This partnership provides access to Stryker's expertise, resources, and distribution network, accelerating the development and commercialization of Microbot Medical's technologies. Future partnerships with other medical device companies or healthcare providers could further expand its market reach and product portfolio. The timeline for realizing the benefits of these partnerships depends on the successful execution of joint development programs and commercial agreements.
• Expanding Intellectual Property Portfolio: Microbot Medical's growing patent portfolio provides a competitive advantage and protects its innovative technologies. Continued investment in research and development and securing additional patents will strengthen its market position and attract potential partners. The value of its intellectual property will increase as its technologies advance through clinical trials and regulatory approvals. A strong IP portfolio is crucial for long-term growth and sustainability in the medical device industry.

What Opportunities Does MBOT Have?

• Expanding market for minimally invasive surgery.
• Potential for additional strategic partnerships.
• Growing demand for robotic surgical solutions.
• Opportunity to address unmet needs in endovascular interventions.

What Threats Does MBOT Face?

• Competition from established medical device companies.
• Regulatory hurdles and delays.
• Technological obsolescence.
• Economic downturn affecting healthcare spending.

What Are MBOT's Competitive Advantages?

• Proprietary robotic technologies (ViRob, TipCAT, CardioSert, Liberty).
• Strong intellectual property portfolio (42 issued/allowed patents).
• Strategic collaboration with Stryker Corporation.
• Focus on a niche market (endoluminal surgery).

What Does MBOT Do?

Founded in 2010 and based in Hingham, Massachusetts, Microbot Medical Inc. is a pre-clinical medical device company dedicated to the research, design, and development of advanced robotic endoluminal surgery devices. The company operates in the minimally invasive surgery space, aiming to transform how surgical procedures are performed. Microbot Medical's core technologies include ViRob, a self-propelled, disposable robot designed for single-use endovascular interventional procedures; TipCAT, a modular robotic system; CardioSert, and Liberty micro-robotic technologies. These technologies are being developed for various applications, including a Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as solutions for endovascular interventions. Microbot Medical has a multi-generation pipeline portfolio supported by an intellectual property estate comprising 42 issued/allowed patents and 23 patent applications pending worldwide. A key strategic alliance is a technology co-development agreement with Stryker Corporation, enhancing its development and commercialization prospects. Currently, the company is in the pre-clinical stage, focusing on research and development to bring its innovative robotic solutions to market.

What Products and Services Does MBOT Offer?

• Develops robotic endoluminal surgery devices.
• Focuses on minimally invasive surgical solutions.
• Designs and researches micro-robotic technologies.
• Creates devices for hydrocephalus treatment.
• Develops disposable robots for endovascular procedures.
• Builds a multi-generation pipeline portfolio.

How Does MBOT Make Money?

• Develops and patents robotic medical devices.
• Seeks strategic collaborations for technology co-development.
• Aims to commercialize its technologies through regulatory approvals.
• Generates revenue through product sales and licensing agreements (future).

What Industry Does MBOT Operate In?

The medical instruments and supplies industry is experiencing significant growth, driven by an aging population, increasing demand for minimally invasive procedures, and technological advancements in robotics and imaging. The global market for surgical robots is projected to reach billions of dollars by 2028, with a compound annual growth rate (CAGR) of over 10%. Microbot Medical operates in this dynamic landscape, competing with established players like Intuitive Surgical and Medtronic, as well as emerging companies focused on specialized robotic solutions. The company's focus on endoluminal surgery positions it within a niche segment of the broader surgical robotics market, offering potential for differentiation and growth.

Who Are MBOT's Key Customers?

• Hospitals and surgical centers.
• Interventional physicians and surgeons.
• Patients requiring minimally invasive procedures.
• Strategic partners like Stryker Corporation.

Company Profile

Microbot Medical Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Hingham, US. The company is led by CEO Harel Gadot. MBOT has traded publicly since 1992.

How Microbot Medical Inc. Is Valued

Microbot Medical Inc. carries a market capitalization of $87.89M, placing it in the micro-cap category. Relative to its peer group, MBOT's quantitative score of 28/100 is below the peer average of 62/100.

ROE -22%Key Financial Metrics

Return on equity for Microbot Medical Inc. stands at -21.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 22.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Microbot Medical Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.88 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Microbot Medical Inc. revenue of about $4.6M for fiscal 2026, with EPS near $-0.29.

MBOT Financials

MBOT Latest News

MBOT Analyst Consensus

MBOT MoonshotScore

Latest Microbot Medical Inc. Analysis

MBOT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources